Proposal for GE

GE is asked to consider the following proposal and the attached paper:

- The clinical guideline CG146: Osteoporosis should not undergo a surveillance review at the 2-year timepoint.
- The next surveillance review should be scheduled to begin after the MTAs to replace TA160, 161 and 204 have completed.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE  
Centre for Clinical Practice – Surveillance Programme  

Decision on surveillance strategy for CG146: Osteoporosis: assessing the risk of fragility fracture

Background information
Guideline issue date: August 2012

1. Two year surveillance reviews are currently based on related Evidence Update products as outlined in the interim clinical guideline surveillance process and methods guide 2013. The related NICE Evidence Update is used as the basis for judgements about changes in evidence since guideline publication.

Surveillance strategy decision

2. A surveillance review decision on the clinical guideline CG146: Osteoporosis should not be undertaken at the 2-year surveillance timepoint.

Factors influencing the decision

3. At Guidance Executive on 8 April 2014 it was agreed that an Evidence Update on this topic would no longer be required for the following reason:
   a. There were a number of earlier TAs relating to two generations of treatment for osteoporosis. These TAs were based on a risk assessment tool which was, subsequently, altered in context by CG146. Technology Appraisals have undertaken a feasibility study to bring the TAs in line with the clinical guideline and this formed the basis of the decision to conduct MTAs to replace TA160, 161 and 204.
   b. On this basis, any amendments to the risk assessment approach at this time would not enable a consistent approach across programmes.

4. Given the forthcoming MTAs, a surveillance decision on CG146: Osteoporosis is no longer required at the 2-year timepoint.
Implications for other NICE programmes
5. A Quality Standard on osteoporosis has been referred with a provisional start date still to be agreed.

Conclusion
6. Based on the above information it is proposed that the clinical guideline CG146: Osteoporosis should not undergo a surveillance review at the 2-year timepoint. The next surveillance review should be scheduled to begin after the MTAs to replace TA160, 161 and 204 have completed.

Mark Baker – Centre Director
Sarah Willett – Associate Director
Emma McFarlane – Technical Adviser

Centre for Clinical Practice
January 2015